Anticoagulant Activity in Cell-Free Peritoneal Fluid of an Experimental Pancreatic Ascites Tumor

Summary

The ascitic form of a chemically-induced pancreatic ductal adenocarcinoma in the Syrian golden hamster was very bloody and indistinguishable from blood macroscopically. Unlike blood, the bloody fluid remained unclotted at room temperature. To explore the possibility of presence of anticoagulants, we mixed 40% cell-free fluid with 60% normal human plasma and tested the clottability of the mixture with standard techniques. Plasma containing the fluid showed markedly prolonged activated partial thromboplastin time (APTT), thrombin time (TT) and recalcification time (RCT), and normal prothrombin time (PT) and reptilase time (RT). Comparing the prolongation of APTT of samples containing the fluid to those containing a commercial heparin, the fluid contained an anticoagulant activity equivalent to 0.436 ± 0.03 unit heparin per ml (mean ± SEM, n = 14). In addition to prolonging the APTT, TT and RCT, the fluid also inhibited the clotting and amidolytic activities of thrombin. “Heparsorb” had nearly completely neutralized the anticoagulant activity in fluid samples, while protamine sulfate was only partially effective. Incubation of fluid with pronase or phospholi-pase did not affect its anticoagulant activity; incubation with heparinase had only a minimal effect. Electrophoresis of an alkali digested fluid on cellulose acetate revealed the presence of heparan sulfate. The native ascitic fluid also contained other hemostatic components including platelets, fibrinogen and antithrombin III, but their concentrations were much lower than in blood. Apparently, heparan sulfate in the neoplastic effusion is largely responsible for the bloody ascites tumor remaining unclotted.

Key words

Experimental pancreatic adenocarcinoma - Neoplastic effusion - Anticoagulant - Heparan sulfate

• References

• 1 Scarpelli DG, Rao MS. Transplantable ductal carcinoma of Syrian hamster pancreas. Cancer Res 1979; 39: 452-458
• 2 Reddy JK, Scarpelli DG, Rao MS. Experimental pancreatic carcinogenesis. In “Advances in Medical Oncology, Research and Education”. Vol9, Thatcher editor Pergamon Press; New York: 1979: 99-107
• 3 Mitchell GA, Hudson PM, Huseby RM, Pochron SP, Gargiulo RG. Fluorescent substrate assay for antithrombin III. Thromb Res 1978; 12: 219-225
• 4 Janett MP, Green D, Ts’ao C. Relation between antithrombin III and clinical and serological parameters in systemic lupus erythematosus. J Clin Pathol 1983; 36: 357-360
• 5 Kanwar YS, Farquhar MG. Isolation of glycosaminoglycans (heparan sulfate) from glomerular basement membrane. Proc Natl Acad Sci 1979; 76: 4493-4497
• 6 Clauss A. Rapid physiological coagulation method for the determination of fibrinogen. Acta Haematol 1957; 17: 237-246
• 7 Smith RT, Ts’ao C. Fibrin degradation products in the postoperative period. Evaluation of a new latex agglutination method. Am J Clin Pathol 1973; 60: 644-647
• 8 Donati MB, Poggi A. Malignancy and haemostasis (Annotation). Br J Haematol 1980; 44: 173-182
• 9 Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastasis. Ann Intern Med 1981; 95: 636-641
• 10 Mehta P. Potential role of platelets in the pathogenesis of tumor metastasis. Blood 1984; 63: 55-63
• 11 Markus G. The role of hemostasis and fibrinolysis in the metastatic spread of cancer. Sem Thromb Hemostas 1984; 10: 61-70
• 12 O’Meara RA Q. Coagulative properties of cancer. Ir J Med Sci 1958; 394: 474-479
• 13 Pineo GF, Regoeczi E, Hatton MW C, Brain MC. The activation of coagulation by extracts of mucus. A possible pathway of intravascular coagulation accompanying adenocarcinoma. J Lab Clin Med 1973; 82: 255-266
• 14 Gasic GJ, Koch PA G, Hsu B, Gasic TB, Niewiarowski S. Thrombogenic activity of mouse and human tumors. Effect on platelets, coagulation and fibrinolysis, and possible significance for metastasis. Z Krebsforsch 1976; 86: 263-277
• 15 Dvorak HF, Von DeWater L, Bitzer AM, Dvorak AM, Anderson D, Harvey S, Bach R, Davis GL, DeWolf V, Carvolho A. Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res 1983; 43: 4334-4337
• 16 Bastida E, Ordinas A, Escolar G, Jamieson GA. Tissue factor in microvesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation, and thrombogenesis. Blood 1984; 64: 177-184
• 17 Gordon SG, Frank JJ, Lewis B. Cancer procoagulant A: A factor X activating procoagulant from malignant tissue. Thromb Res 1975; 6: 127-137
• 18 Curatolo L, Colucci M, Cambini AL, Poggi A, Morasca L, Donati MB, Semeraro N. Evidence that cells from experimental tumours can activate factor X. Br J Cancer 1979; 40: 228-233
• 19 Glueck HE, Hong R. A circulating anticoagulant in 1-A multiple myeloma. Its modification by penicillin. J Clin Invest 1965; 44: f1866-f1881
• 20 Vigliano EM, Horowitz H. Bleeding syndrome in a patient with IgA myeloma: Interaction of protein and connective tissue. Blood 1967; 6: 823-836
• 21 Chen I, Amiv J, Ben-Shaul Y, Pick A, DeVries A. Plasma cell myeloma associated with an unusual myeloma protein causing impairment of fibrin aggregation and platelet function in a patient with multiple malignancy. Am J Med 1970; 48: 766-776
• 22 Lackner H, Hunt V, Zucker MB, Pearson J. Abnormal fibrin ultrastructure, polymerization and clot retraction in multiple myeloma. Br J Haematol 1970; 18: 625-636
• 23 Benda L, Deutsch E, Mammen E. Über eine Gerinnungsstorung bei einem Patienten mit multiplem Myelom. Wien Klin Wochenschr 1958; 70: 559-562
• 24 Favre-Gilly J, Creyssel R, Thouverez JP, Revol L, Croizat P. Antithrombine du type de l’heparine dans un gamma-myelome. Considerations sur les anticoagulants spontanes dans la maladie de Kahler. Hémostase 1963; 3: 325-333
• 25 Khoory MS, Nesheim ME, Bowie EJ W, Mann KG. Circulating heparan sulfate anticoagulant from a patient with a plasma cell disorder. J Clin Invest 1980; 65: 666-674
• 26 Palmer RN, Rick ME, Rick PD, Zeller JA, Gralnick HR. Circulating heparan sulfate anticoagulant in a patient with a fatal bleeding disorder. N Engl J Med 1984; 310: 1696-1699
• 27 Chapman GS, George CB, Danley DL. Heparin-like anticoagulant associated with plasma cell myeloma. Am J Clin Pathol 1985; 83: 764-766
• 28 Bussel JB, Steinherz PG, Miller DR, Hilgartner MW. A heparinlike anticoagulant in an 8-month old with acute monoblastic leukemia. Am J Hematol 1984; 16: 83-90
• 29 Hubbard AR, Jennings CA. Neutralisation of heparan sulfate and low molecular weight heparin by protamine. Thromb Haemostas 1985; 53: 86-89
• 30 Johnson EA. Heparan sulfates from porcine intestinal mucosa. Preparation and physiochemical properties. Thromb Res 1984; 35: 583-588
• 31 Wever J, Schachtschabel DO, Sluke G, Wever G. Effect of short- or long-term treatment with exogenous glycosminoglycans on growth and glycosaminoglycan synthesis of human fibroblasts (WI-38) in culture. Mech Age Develop 1980; 14: 89-99
• 32 Johnston LS, Keller KL, Keller JM. The heparan sulfate of Swiss mouse 3T3 cells. The effect of transformation. Biochim Biophys Acta 1979; 583: 81-94
• 33 Matuoka K, Mitsui Y. Involvement of cell surface heparan sulfate in the density-dependent inhibition of cell proliferation. Cell Struct Funct 1981; 6: 23-33
• 34 Matuoka K, Mitsui Y, Murota S. Heparan sulfate enhances growth of transformed human cells. Cell Struct Funct 1984; 9: 357-367
• 35 Brawley RK. Autotransfusion in postoperative cardiac surgical patients. In “Autotransfusion” Hauer H, Thurer T, Dawson D. (Eds). Elsevier: Holland: 1981: 51-62
• 36 Symbas PN. Autotransfusion in thoracic trauma. In “Autotransfusion” Hauer H, Thurer T, Dawson D. (Eds). Elsevier: Holland: 1981: 83-92